Microalgal Strain Promoter Engineering Patents: Leaders & Trends 2026
- 71.0% of all 217 records sit with just five assignees, and 88.0% with ten — this is a field with a short list of gatekeepers, not a crowded open market.
- Filing growth sits at 0% from 2021 to 2024, the last complete year window in this dataset, after a 2018 peak of 20 filings — the surge that built this field has already happened.
- C12P fermentation claims cover 67.7% of records while medicinal-use claims under A61K sit at just 7.8%, pointing to a strain-engineering field still framed almost entirely around production, not therapeutics.
Filing growth compares 2021 (1 records) with 2024 (1) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 217 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent families combining microalgal cell or strain terminology with promoter-engineering language — promoter mutation, operator sequence, transcription strength, inducible promoter, constitutive promoter and reporter assay — filed under the microorganism, fermentation and enzymatic-assay IPC classes. It spans 217 published records filed between 2015 and mid-2026, giving a reasonably tight view of who is actually claiming control over gene-expression tuning in engineered microalgae, as opposed to strain discovery or downstream product claims more broadly.
Because publication typically lags filing by around 18 months, the most recent one to two years in any trend understate real filing activity — 2026 in particular should be read as incomplete rather than as a genuine drop-off.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 217 records: how filing activity has moved year over year, and how those records split across the IPC classes that define the technology's edges.
A field that peaked and plateaued
Filings ran from 10 in 2017 to a peak of 20 in 2018, then settled into a much flatter pattern. Growth from 2021 to 2024 — the last window unaffected by publication lag — sits at 0%, meaning the field is neither expanding nor contracting on the evidence in hand; it has simply stopped growing after its initial build-out.
Fermentation and synthesis dominate the claim map
C12N (microorganisms and genetic engineering) touches 94.5% of the 217 records and C12P (fermentation and enzymatic synthesis) touches 67.7%, confirming that promoter engineering here is claimed overwhelmingly as a production tool. Peptide chemistry (C07K, 16.1%), fuel applications (C10L, 14.3%), animal feed (A23K, 12.0%) and bioreactor hardware (C12M, 12.0%) form a second tier of adjacent claim territory, while medicinal preparations (A61K, 7.8%) remain a comparatively small slice.
Shares are the percentage of the 217 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Microalgal Strain Promoter Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about microalgal strain promoter engineering and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited foundational filings
Chlorophyllase overproduction to enhance photosynthetic efficiency (WO2017160573A1)
Recombinant microorganisms and methods for using the same are disclosed herein for producing biomass or at least one biomolecule. These methods comprise culturing a photosynthetic microorganism that can overexpress a chlorophyllase, and optionally isolating biomass and/or at least one biomolecule from the culture.Filed by ExxonMobil Research and Engineering Company, this filing illustrates how promoter and expression-tuning claims in this space get wrapped inside a broader biomass or biomolecule production method rather than claimed as a standalone promoter invention.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2010063032A2 | Production of tailored oils in heterotrophic microorganisms | 201 |
| 2 | WO2010063031A2 | Manufacturing of tailored oils in recombinant heterotrophic microorganisms | 172 |
| 3 | US20100151112A1 | Novel Triglyceride and Fuel Compositions | 165 |
| 4 | US20090035842A1 | Sucrose Feedstock Utilization for Oil-Based Fuel Manufacturing | 136 |
| 5 | US7935515B2 | Recombinant microalgae cells producing novel oils | 122 |
| 6 | US20110294174A1 | Tailored Oils Produced From Recombinant Heterotrophic Microorganisms | 116 |
| 7 | US20110047863A1 | Production of Oil in Microorganisms | 105 |
| 8 | US8187860B2 | Recombinant microalgae cells producing novel oils | 95 |
| 9 | US20120288930A1 | Lipid Pathway Modification in Oil-Bearing Microorganisms | 76 |
| 10 | US20100151539A1 | Recombinant Microalgae Cells Producing Novel Oils | 76 |
Citation counts accumulate over time, so older filings — several from around 2010 — lead the table. Treat this as a measure of historical influence on the field's foundations, not of which claims matter most today.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for strategy
Three patterns stand out once the filing trend, the IPC composition and the assignee concentration are read together.
A short list of gatekeepers, not an open field
With five assignees holding 71.0% of all 217 records and ten holding 88.0%, most viable promoter-engineering claim territory in microalgae has already been staked out by a small group of filers. A new entrant is more likely to be designing around existing claims than filing into open space.
The build-out phase is over
Filing peaked at 20 in 2018 and has since flattened, with 0% growth across the 2021–2024 window that isn't distorted by publication lag. That does not mean the underlying science is finished — it means the patenting rush that followed the field's early breakthroughs has already run its course.
Production framing, not therapeutic framing
Two-thirds of records carry a C12P fermentation/synthesis class alongside the core C12N genetic-engineering class, against just 7.8% touching A61K medicinal preparations. Promoter engineering in microalgae is being claimed almost entirely as a manufacturing lever for biomass, oils and feed, leaving therapeutic and biomolecule-extraction framing comparatively open.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to microalgal strain promoter engineering, with the prior art for and against each one.
Who holds the claim space
The ranked leaders in this dataset cover 29 companies. Filing activity is heavily front-loaded to a handful of biofuel- and biomass-focused names from the field's 2017-2018 peak, several of which show no filings in the most recent tracked year.
One filer sits well clear of the field
The top-ranked assignee holds 52 records against a fifth-place figure of 20 and a tenth-place figure of 4 — a steep drop-off that marks this as a field with one dominant filer, a mid-tier of active competitors, and a long tail of single- or few-filing entrants.
A small, tightly linked inventor cluster
Co-assignment activity is concentrated in a small set of pairs, with the three strongest pairs — built around the same three named inventors — each sharing 5 filings. This points to a compact R&D team whose internal collaboration accounts for a disproportionate share of the co-filed record.
Several early leaders have gone quiet
A number of assignees prominent in the field's 2017-2018 build-out show zero filings in the most recent tracked year, including one with a recorded -100% year-over-year change. That is consistent with a field past its initial patenting rush rather than one still accelerating.
| Assignee | Recent year | YoY |
|---|---|---|
| Solazyme Inc | 0 | — |
| Synthetic Genomics Inc | 0 | — |
| Phycoil Biotechnology International Inc | 0 | — |
| Research Institute at Nationwide Children's Hospital | 0 | -100% |
| TerraVia Holdings Inc | 0 | — |
| TransAlgae Israel | 0 | — |
| Corbion Biotech Inc | 0 | — |
| FRANKLIN SCOTT | 0 | — |
Where to take this
The dataset points to a field with settled leadership and flattened filing activity, but leaves several practical questions open for a team deciding where to file or partner.
Map the top assignees' live claim boundaries
With 71.0% of records held by five filers, the practical next step is a claim-by-claim read of those portfolios rather than a further landscape scan.
Explore assignee portfolios in EurekaStress-test a design-around against the most-cited filings
The most-cited records in this set date to around 2010-2011 and still anchor freedom-to-operate analysis for new promoter constructs.
Run a claim comparison in EurekaSize the under-claimed branches before committing R&D
Therapeutic-framed and reporter-assay-standardisation claims sit well below the fermentation-focused core; validating that gap against live applications is worth doing before drafting.
Check white space in EurekaFrequently asked questions
The dataset's top-ranked assignee holds 52 of the 217 records in scope, well ahead of the fifth-ranked filer at 20 and the tenth-ranked filer at 4. Together the top five assignees account for 71.0% of all records, and the top ten account for 88.0%. This means the field's competitive landscape is defined by a small number of established filers rather than a wide field of equally weighted players, so due-diligence work should start with those portfolios rather than a broad search.
No — filings peaked at 20 in 2018, and the growth rate across 2021 to 2024, the most recent window not distorted by publication lag, sits at 0%. That does not mean research has stopped; it means the initial patenting rush that followed the technology's early breakthroughs has run its course. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so a real read on the most current activity will take another year or two of data to confirm.
C12N, covering microorganisms and genetic engineering, appears in 94.5% of the 217 records, and C12P, covering fermentation and enzymatic synthesis, appears in 67.7%. Smaller but notable shares fall under C07K peptides and proteins (16.1%), C10L fuels (14.3%), A23K animal feed (12.0%), and C12M bioreactor apparatus (12.0%). Because a single record can carry several IPC classes, these shares add up to more than 100% and should be read as overlapping technology footprints, not as mutually exclusive categories.
WO2017160573A1, filed by ExxonMobil Research and Engineering Company and published in September 2017, covers recombinant photosynthetic microorganisms engineered to overexpress a chlorophyllase enzyme, used for producing biomass or a target biomolecule. The claims are framed around a production method — culturing the engineered organism and optionally isolating biomass or biomolecule output — rather than around a standalone promoter-tuning mechanism. Anyone using chlorophyllase overexpression as a route to improved photosynthetic efficiency in microalgae should read this filing's claim scope closely before assuming a design-around is unnecessary.
The clearest gap sits away from the dominant fermentation and biomass framing that covers 67.7% of records: therapeutic and biomolecule-extraction applications (A61K, 7.8% of records) remain comparatively thin, as does reporter-assay standardisation and feed-grade operator-sequence tuning. These are areas where the dominant filers have built less claim density, making them a more promising starting point for new filings than the crowded C12N/C12P core. Any first claim in these areas should still be checked against the top assignees' broader portfolios, since some may hold platform-level claims that reach into adjacent applications.
Research Microalgal Strain Promoter Engineering in depth with Eureka
Go past this page: query the whole microalgal strain promoter engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.